-
Mashup Score: 1Webprogram Unavailable - 7 month(s) ago
Please click HERE if you are not redirected in 5
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Webprogram Unavailable - 1 year(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Impact of Chromosome 1 Abnormalities Among Pts w/ Newly Diagnosed Multiple Myeloma: A Subgroup Analysis from the Endurance (#EAonc E1A11) Trial [oral: 12/12/21] @TMSchmidtMD et al. @myelomaMD @eaonc Abstract 467 #ASH21 https://t.co/HaaZ5tEEPT #NCT01863550 #mmsm #PrecisionMedicine https://t.co/w5KRy1KUrq
-
-
Mashup Score: 1Webprogram Unavailable - 2 year(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Impact of Chromosome 1 Abnormalities Among Pts w/ Newly Diagnosed Multiple Myeloma: A Subgroup Analysis from the Endurance (#EAonc E1A11) Trial [oral: 12/12/21] @TMSchmidtMD et al. @myelomaMD @eaonc Abstract 467 #ASH21 https://t.co/HaaZ5tEEPT #NCT01863550 #mmsm #PrecisionMedicine https://t.co/d0BsgfmYTl
-
-
Mashup Score: 3
Oral and Poster Abstracts Oral 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials; treatment of NDMM and amyloidosis patients Clinical Trials, Adults, Clinical Research, Plasma Cell Disorders, Clinically Relevant, Diseases, Lymphoid Malignancies, Study Population Timothy Martin Schmidt, MD1, Prashant Kapoor, MD2,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Impact of Chromosome 1 Abnormalities Among Pts w/ NDMM: A Subgroup Analysis from the Endurance (#EAonc E1A11) Trial [oral: 12/12/21] @TMSchmidtMD et al. @myelomaMD @eaonc Abstract 467 #ASH21 https://t.co/HaaZ5tEEPT #NCT01863550 #mmsm #PrecisionMedicine Conclusions https://t.co/MLJauNcqEB
-
Impact of Chromosome 1 Abnormalities Among Pts w/ Newly Diagnosed Multiple Myeloma: A Subgroup Analysis from the Endurance (#EAonc E1A11) Trial [oral: 12/12/21] @TMSchmidtMD et al. @myelomaMD @eaonc Abstract 467 #ASH21 https://t.co/HaaZ5tEEPT #NCT01863550 #mmsm #PrecisionMedicine https://t.co/cpVTw1dlZr
-
-
Mashup Score: 0
Oral and Poster Abstracts Oral 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials; treatment of NDMM and amyloidosis patients Clinical Trials, Adults, Clinical Research, Plasma Cell Disorders, Clinically Relevant, Diseases, Lymphoid Malignancies, Study Population Timothy M. Schmidt, MD1, Prashant Kapoor, MD2,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Impact of Chromosome 1 Abnormalities Among Pts w/ Newly Diagnosed Multiple Myeloma: A Subgroup Analysis from the Endurance (#EAonc E1A11) Trial [oral: 12/12/21] @TMSchmidtMD et al @myelomaMD @eaonc Abstract 467 #ASH21 https://t.co/HaaZ5tEEPT #NCT01863550 #mmsm #PrecisionMedicine https://t.co/tAKNVKC1Y2
-
-
Mashup Score: 0Meeting Library | Meeting Library - 4 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2020 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
KRd vs VRd for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE @eaonc E1A11 phase 3 trial - @myelomaMD et al. @VincentRK LBA3 #ASCO20 https://t.co/bQpaBaHxe4 #NCT01863550 #mmsm #EAonc https://t.co/YD25mAntpo
-
-
Mashup Score: 6Meeting Library | Meeting Library - 4 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2020 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
KRd vs VRd for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE @eaonc E1A11 phase 3 trial - @myelomaMD et al. @VincentRK LBA3 #ASCO20 https://t.co/bQpaBaHxe4 #NCT01863550 #mmsm #EAonc https://t.co/4oHrjCdfIF
-
-
Mashup Score: 0Meeting Library | Meeting Library - 4 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2020 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Carfilzomib, lenalidomide & dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE @eaonc E1A11 phase 3 trial - @myelomaMD et al. LBA3 https://t.co/bQpaBaHxe4 #NCT01863550 #mmsm
-
-
Mashup Score: 5Meeting Library | Meeting Library - 4 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2020 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#EAonc E1A11 ENDURANCE Ph3: KRd vs VRd in NDMM - @myelomaMD et al. LBA3 https://t.co/bQpaBaHxe4 #NCT01863550 #mmsm @eaonc https://t.co/ZHUIU3EaDC
-
-
Mashup Score: 0Meeting Library | Meeting Library - 4 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2020 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Carfilzomib, lenalidomide & dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE @eaonc E1A11 phase 3 trial - @myelomaMD et al. LBA3 https://t.co/bQpaBaHxe4 #NCT01863550 #mmsm
-
Impact of Chromosome 1 Abnormalities Among Pts w/ Newly Diagnosed Multiple Myeloma: A Subgroup Analysis from the Endurance (#EAonc E1A11) Trial [oral: 12/12/21] @TMSchmidtMD et al. @myelomaMD @eaonc Abstract 467 #ASH21 https://t.co/HaaZ5tEEPT #NCT01863550 #mmsm #PrecisionMedicine https://t.co/CAN5w5Mt1Y